Efbemalenograstim alfa

Recent clinical trials demonstrate that same-day administration of granulocyte colony-stimulating factors (G-CSFs) after chemotherapy is safe and effective in patients with early-stage breast cancer, potentially simplifying treatment protocols.

The EMA's human medicines committee has refused marketing approvals for drugs from Neuraxpharm and Apellis, citing lack of clinically meaningful benefits and concerns over tolerability. Both companies plan to appeal the decisions.